56.83
1.66%
0.74
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Precedente Chiudi:
$56.09
Aprire:
$56.16
Volume 24 ore:
27,963
Relative Volume:
0.03
Capitalizzazione di mercato:
$5.88B
Reddito:
$628.56M
Utile/perdita netta:
$141.82M
Rapporto P/E:
70.16
EPS:
0.81
Flusso di cassa netto:
$142.60M
1 W Prestazione:
+4.07%
1M Prestazione:
+16.11%
6M Prestazione:
+97.99%
1 anno Prestazione:
+124.31%
Corcept Therapeutics Inc Stock (CORT) Company Profile
Nome
Corcept Therapeutics Inc
Settore
Industria
Telefono
650.688.8803
Indirizzo
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Confronta CORT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
CORT | 56.91 | 5.88B | 628.56M | 141.82M | 142.60M | 0.81 |
VRTX | 449.15 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 744.75 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 589.91 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.60 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.56 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-11-06 | Aggiornamento | Truist | Hold → Buy |
2023-04-11 | Iniziato | SVB Securities | Market Perform |
2023-04-04 | Iniziato | Piper Sandler | Overweight |
2023-02-15 | Downgrade | Jefferies | Buy → Hold |
2022-08-01 | Downgrade | Truist | Buy → Hold |
2022-07-27 | Aggiornamento | Jefferies | Hold → Buy |
2022-06-27 | Ripresa | Canaccord Genuity | Buy |
2022-02-02 | Iniziato | Canaccord Genuity | Buy |
2022-01-28 | Iniziato | Truist | Buy |
2020-08-05 | Downgrade | Jefferies | Buy → Hold |
2019-09-24 | Iniziato | Jefferies | Buy |
2019-09-06 | Iniziato | H.C. Wainwright | Buy |
2019-02-04 | Downgrade | B. Riley FBR | Buy → Neutral |
2018-08-10 | Reiterato | Stifel | Hold |
2018-05-31 | Downgrade | Stifel | Buy → Hold |
2018-03-09 | Iniziato | B. Riley FBR, Inc. | Buy |
2017-08-31 | Iniziato | Stifel | Buy |
2017-02-02 | Iniziato | Ladenburg Thalmann | Buy |
2015-04-21 | Iniziato | FBR Capital | Outperform |
2014-01-13 | Downgrade | Stifel | Buy → Hold |
2013-08-09 | Downgrade | Janney | Buy → Neutral |
2013-08-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
2012-02-21 | Reiterato | JMP Securities | Mkt Outperform |
2010-01-06 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
2008-07-17 | Iniziato | Rodman & Renshaw | Mkt Outperform |
2007-06-21 | Aggiornamento | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Mostra tutto
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
Empowered Funds LLC Makes New Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet - Yahoo Finance
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Cornercap Investment Counsel Inc. Has $426,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Royce & Associates LP Has $16.81 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Teva Defends Mifepristone Antitrust Case Against Corcept - Law360
Intellectus Partners LLC Purchases Shares of 54,859 Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $65.25 Average Target Price from Analysts - Defense World
Corcept Therapeutics director Daniel Swisher sells $131,736 in stock By Investing.com - Investing.com Australia
Principal Financial Group Inc. Sells 20,770 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics director Daniel Swisher sells $131,736 in stock - Investing.com
Corcept (CORT) Upgraded to Strong Buy: Here's Why - MSN
Cushing's Syndrome Market to Show a Rise During the Study Period | - openPR
Cushing's Syndrome Market Will Drive an Exponential CAGR - openPR
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
24,800 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Acquired by Versor Investments LP - MarketBeat
Wealth Enhancement Advisory Services LLC Takes $238,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Lisanti Capital Growth LLC Increases Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
CWA Asset Management Group LLC Acquires Shares of 20,800 Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Robeco Institutional Asset Management B.V. Trims Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy? - MSN
Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 8.9%Time to Buy? - MarketBeat
US Bancorp DE Purchases 12,177 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
M&G Plc Buys New Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? - MSN
New York State Teachers Retirement System Sells 17,222 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics' chief development officer sells $489,700 in stock - Investing.com
Corcept Therapeutics' chief development officer sells $489,700 in stock By Investing.com - Investing.com UK
Here is Why Growth Investors Should Buy Corcept (CORT) Now - Yahoo Finance
Corcept Stock At New High; Will The Upcoming Regulatory And Clinical Trial Catalysts Take It Higher? - RTTNews
Roman Butler Fullerton & Co. Has $261,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Creative Planning Acquires 841 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics stock soars to all-time high of $50.23 - Investing.com India
Corcept Therapeutics (NASDAQ:CORT) Sets New 1-Year HighWhat's Next? - MarketBeat
Corcept Therapeutics stock soars to all-time high of $50.23 By Investing.com - Investing.com Australia
Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade - Yahoo Finance
Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why - Yahoo Canada Finance
What is HC Wainwright’s Forecast for CORT FY2024 Earnings? - Defense World
HC Wainwright Has Bullish Forecast for CORT FY2024 Earnings - MarketBeat
What is HC Wainwright’s Estimate for CORT FY2026 Earnings? - Defense World
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View - MSN
Corcept Therapeutics (CORT) Stock Declines Amid Market Activity - GuruFocus.com
Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy? - MSN
Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.2%Here's What Happened - MarketBeat
FY2026 Earnings Estimate for CORT Issued By HC Wainwright - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2024 Earnings Call Transcript - Insider Monkey
Corcept’s relacorilant GRADIENT trial misses primary endpoint - Yahoo Finance
Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Corcept Therapeutics reports robust Q3 growth, raises guidance - Investing.com Canada
Corcept Therapeutics Inc Azioni (CORT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):